DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20220737

A randomized, double-blind, parallel, placebo-controlled study to evaluate efficacy and safety of a synergistic multi-herbal extract blend KaraHeart™ in supporting healthy cholesterol levels

Krishna Rajendran, Rajendran Ramaswamy, Sucharitha L., Ravikumar Rajendran, Ramachandra Bharadwaja, Latha K., Dheeraj Kumar Deep

Abstract


Background: Hyperlipidemia is a condition involving abnormally high levels of lipids in the blood. Hyperlipidemia is a major risk factor for cardiovascular diseases and refers to either high levels of triglycerides (TGL) or cholesterol. Herbal supplements have been used in the management of cholesterol levels in Ayurveda, a complete medical system originating in India. KaraHeart is a multi-herbal extract synergistic blend that may help in the management of healthy cholesterol levels. The current study tested the efficacy, tolerability, and safety of KaraHeart versus a placebo in the management of cholesterol levels of patients with mild hyperlipidemia.

Methods: This was a randomized, double-blind, parallel, and placebo-controlled study. A total of 100 patients were divided into two groups. One group was given KaraHeart and the other group was given a placebo for 120 days. Treatment results were assessed by checking the lipid profile parameters such as total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and TGL.

Results: The study found that the herbal supplement KaraHeart significantly reduced levels of LDL, VLDL, TGL, and total cholesterol, while increasing the levels of HDL in the blood. Additionally, the study concluded that KaraHeartwas safe to use.

Conclusions: KaraHeart was shown to be safe and effective in the management of cholesterol levels.


Keywords


Healthy cholesterol, Hyperlipidemia, Herbal supplement, Natural treatment, Randomized Clinical trial, Lipid profile

Full Text:

PDF

References


World Health Organization. Global Health Observatory data: Cholesterol, 2021. Available at: http://www.who.int/gho/ncd/risk_factors/cholesterol_prevalence/en/. Accessed on 24 June 2021.

Moor VJ, Amougou S, Ombotto S, Ntone F, Wouamba DE, Nonga B. Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon. Int J Vasc Med. 2017;2017:6061306.

Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In: Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston, MA: Butterworths. 1990;31.

Centres for Disease Control and Prevention. LDL and HDL Cholesterol:“Bad” and “Good” Cholestrol, 2020. Available at: https://www.cdc.gov/cholesterol/ldl_ hdl.htm#:~:text=LDL%20and%20HDL%20Cholesterol%3A%20%22Bad%22%20and%20%22Good%22%20Cholesterol&text=Cholesterol%20travels%20through%20the%20blood,most%20of%20your%20body’s%20cholesterol. Accessed on 20 May 2021.

Lee Y, Siddiqui WJ. Cholesterol levels. StarPearls Publishing. 2019.

Yanai H, Yoshida H. Secondary dyslipidemia: its treatments and association with atherosclerosis. Glob Health Med 2021;3(1):15-23.

Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195-211.

Verma SK, Bordia A. Effect of Commiphora mukul (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol. Indian J Med Res. 1988;87:356-60.

Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8(4):659-64.

Hasani-Ranjbar S, Nayebi N, Moradi L, Mehri A, Larijani B, Abdollahi M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Curr Pharm Des. 2010;16(26):2935-47.

Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296(5573):1703-6.

Yu BZ, Kaimal R, Bai S, El Sayed KA, Tatulian SA, Apitz RJ, et al. Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009;72(1):24-8.

Singh S, Parmar N, Patel B. Management of Hridroga (Cardiovascular Disease) with Simple Ayurvedic Drugs. A Review. Research & Reviews: A Journal of Ayurvedic Science, Yoga and Naturopathy. 2016;3(1):12-6.

Jalali MT, Honomaror AM, Rekabi A, Latifi M. Reference ranges for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, and VLDL-cholesterol and triglycerides in healthy ranian ahvaz population. Indian Journal of Clinical Biochemistry. 2013;28(3):277-82.

Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arvelier D, et al. Value of HDL cholesterol, apolipoprotein A1, lipoprotein A1, and lipoprotein A-1/A-II in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol. 2002;22:1155-61.

Rahim S, Abdullah HM, Ali Y, Khan UI, Ullah W, Shahzad MA, et al. Serum Apo A-1 and its role as a biomarker of coronary artery disease. Cureus. 2016;8(12).

Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, Rodriguez-Artalejo F, Martínez-Vizcaíno V. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ open. 2017;7(7):e015949.

Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr atherosclero rep 2006;8(5):421-8.

University of Rochester Medical Centre. Health Encyclopedia-Apolipoprotein A. Available at: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=apolipoprotein_a. Accessed on 7 May 2021.

Azemawah V, Movahed MR, Centuori P, Penaflor R, Riel PL, Situ S et al. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovascular drugs and therapy. 2019;33(5):625-39.

Nelson AJ, Pagidipati NJ, Granger CB. The SAMSON trial: using a placebo to improve medication tolerability. European Heart Journal-Cardiovascular Pharmacotherapy. 2021;21:12-9.

Okopień B, Bułdak Ł, Bołdys A. Benefits and risks of the treatment with fibrates––a comprehensive summary. Expert review of clinical pharmacology. 2018;11(11):1099-112.

Riva A, Petrangolini G, Allegrini P, Perna S, Giacosa A, Peroni G et al. Artichoke and Bergamot Phytosome Alliance: A Randomized Double Blind Clinical Trial in Mild Hypercholesterolemia. Nutrients. 2022;14(1):108.

Cicero AF, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M et al. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75:731-67.